Where it trades today
trading 37% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ABT trades at 33.2x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- ABT carries a beta of 0.59, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- ABT remains in a bearish short-term trend and sits 25.4% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- ABT is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ABT.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ABT come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ABT. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Abbott Laboratories does
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective…
What analysts expect
ABT carries a buy consensus from 25 analysts, with an average price target of $120.26 versus $102.61 today (+17.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ABT generated $46.58B in trailing revenue (13.0% year over year), with a 11.6% net margin, and $7.21B of free cash flow, against $27.12B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $44.33B | $25.01B | $8.05B | $6.52B | $3.76 | $7.39B |
| 2024 | $41.95B | $23.24B | $6.83B | $13.40B | $7.74 | $6.35B |
| 2023 | $40.11B | $22.13B | $6.48B | $5.72B | $3.30 | $5.06B |
| 2022 | $43.65B | $24.51B | $8.36B | $6.93B | $3.99 | $7.80B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ABT beside the healthcare names it is usually measured against.
What the chart is saying
Abbott Laboratories trades at $102.61, 25.4% below its 52-week high. With a beta of 0.59, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is ABT a good buy right now?
Abbott Laboratories trades at 33.2x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 20.4% volatility.
Does ABT pay dividends?
Yes, Abbott Laboratories offers a dividend yield of 2.47%. That is roughly $2.53 per share a year.
How volatile is ABT?
With 30-day annualized volatility of 20.4% and beta of 0.59, ABT is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for ABT?
The average analyst price target for Abbott Laboratories (ABT) is $120.26 based on 25 analyst estimates, about 17.2% above the current price of $102.61. The published range runs from $103.00 to $135.00.
How much revenue does ABT generate?
Abbott Laboratories reported $46.58B in trailing twelve-month revenue. Revenue growth is running at 13.0% year over year. Net margin sits at 11.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.